Dupilumab improves respiratory symptoms in patients with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial

被引：0

作者：

Papi, Alberto ^{[1
]}

Bhatt, Surya P. ^{[2
]}

Rabe, Klaus F. ^{[3
,4
]}

Hanania, Nicola A. ^{[5
]}

Vogelmeier, Claus F. ^{[6
]}

Bafadhel, Mona ^{[7
]}

Christenson, Stephanie A. ^{[8
]}

Singh, Dave ^{[9
]}

Laws, Elizabeth ^{[10
]}

Maloney, Jennifer ^{[11
]}

Lu, Xin ^{[10
]}

Bauer, Deborah ^{[10
]}

Bansal, Ashish ^{[11
]}

Robinson, Lacey B. ^{[12
]}

Abdulai, Raolat M. ^{[12
]}

机构：

[1] Univ Ferrara, Ferrara, Italy

[2] Univ Alabama Birmingham, Birmingham, AL USA

[3] LungenClin Grosshansdorf, Grosshansdorf, Germany

[4] Christian Albrechts Univ Kiel, Airway Res Ctr North, German Ctr Lung Res, Grosshansdorf, Germany

[5] Baylor Coll Med, Houston, TX USA

[6] Philipps Univ Marburg, German Ctr Lung Res DZL, Marburg, Germany

[7] Kings Coll London, Kings Ctr Lung Hlth, London, England

[8] Univ Calif San Francisco, San Francisco, CA USA

[9] Univ Manchester, Manchester Univ NHS Fdn Trust, Manchester, England

[10] Sanofi, Bridgewater, NJ USA

[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[12] Sanofi, Cambridge, MA USA

来源：

EUROPEAN RESPIRATORY JOURNAL | 2024年 / 64卷

关键词：

D O I：

10.1183/13993003.congress-2024.PA4786

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：3

共 50 条

[1] Dupilumab improves quality of life in non-exacerbators with moderate-to-severe COPD and type 2 inflammation: phase 3 BOREAS trial
Rabe, Klaus F.
Vogelmeier, Claus F.
Bhatt, Surya P.
Hanania, Nicola A.
Bafadhel, Mona
Christenson, Stephanie
Papi, Alberto
Singh, Dave
Laws, Elizabeth
Maloney, Jennifer
Lu, Xin
Bauer, Deborah
Bansal, Ashish
Robinson, Lacey B.
Abdulai, Raolat M.
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[2] Dupilumab improves lung function in non-exacerbators with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial
Rabe, Klaus F.
Vogelmeier, Claus F.
Bhatt, Surya P.
Hanania, Nicola A.
Bafadhel, Mona
Christenson, Stephanie A.
Papi, Alberto
Singh, Dave
Laws, Elizabeth
Maloney, Jennifer
Lu, Xin
Bauer, Deborah
Bansal, Ashish
Robinson, Lacey B.
Abdulai, Raolat M.
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[3] Dupilumab Does Not Impact Blood Eosinophil Levels in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: From the Phase 3 Boreas Trial
Bafadhel, M.
Christenson, S. A.
Hanania, N. A.
Bhatt, S. P.
Rabe, K. F.
Vogelmeier, C. F.
Papi, A.
Singh, D.
Laws, E.
Nivens, C.
Bansal, A.
Lu, X.
Bauer, D.
Maloney, J.
Robinson, L. B.
Abdulai, R. M.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
[4] Efficacy and Safety of Dupilumab in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: Phase 3 NOTUS Trial
Bhatt, S. P.
Rabe, K. F.
Hanania, N. A.
Vogelmeier, C. F.
Bafadhel, M.
Christenson, S. A.
Papi, A.
Singh, D.
Laws, E.
Akinlade, B.
Maloney, J.
Lu, X.
Bauer, D.
Bansal, A.
Abdulai, R. M.
Robinson, L. B.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
[5] Dupilumab efficacy and safety in patients with moderate-to-severe COPD with type 2 inflammation: pooled analysis of BOREAS and NOTUS
Bhatt, Surya
Rabe, Klaus F.
Hanania, Nicola
Vogelmeier, Claus F.
Bafadhel, Mona
Christenson, Stephanie
Papi, Alberto
Singh, Dave
Laws, Elizabeth
Akinlade, Bolanle
Maloney, Jennifer
Lu, Xin
Bauer, Deborah
Bansal, Ashish
Abdulai, Raolat M.
Robinson, Lacey B.
Bhatt, Surya
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[6] Dupilumab Improves Post-bronchodilator Lung Function in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the Phase 3 Boreas Trial
Hanania, N. A.
Bhatt, S. P.
Rabe, K. F.
Vogelmeier, C. F.
Bafadhel, M.
Christenson, S. A.
Papi, A.
Singh, D.
Laws, E.
Nivens, C.
Bansal, A.
Lu, X.
Bauer, D.
Maloney, J.
Robinson, L. B.
Abdulai, R. M.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
[7] IN THE PHASE 3 BOREAS TRIAL, DUPILUMAB REDUCED FENO LEVELS OVER TIME IN PATIENTS WITH MODERATE OR SEVERE SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH TYPE 2 INFLAMMATION
Bhatt, Surya P.
Christenson, Stephanie
Hanania, Nicola A.
Bafadhel, Mona
Rabe, Klaus F.
Vogelmeier, Claus
Papi, Alberto
Singh, Dave
Laws, Elizabeth
Dakin, Paula
Bansal, Ashish
Lu, Xin
Bauer, Deborah
Maloney, Jennifer
Robinson, Lacey
Abdulai, Raolat
CHEST, 2024, 166 (04) : 4835A - 4839A
[8] IN PATIENTS WITH MODERATE OR SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION, DUPILUMAB DOES NOT IMPACT BLOOD EOSINOPHIL LEVELS: PHASE 3 BOREAS TRIAL
Bafadhel, Mona
Christenson, Stephanie
Hanania, Nicola A.
Bhatt, Surya P.
Vogelmeier, Claus
Papi, Alberto
Singh, Dave
Laws, Elizabeth
Dakin, Paula
Bansal, Ashish
Lu, Xin
Bauer, Deborah
Maloney, Jennifer
Robinson, Lacey
Abdulai, Raolat
CHEST, 2024, 166 (04) : 4831A - 4834A
[9] DUPILUMAB IMPROVES RESPIRATORY SYMPTOMS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: POOLED RESULTS FROM BOREAS AND NOTUS
Bhatt, Surya P.
Rabe, Klaus F.
Hanania, Nicola A.
Vogelmeier, Claus
Bafadhel, Mona
Christenson, Stephanie
Papi, Alberto
Singh, Dave
Laws, Elizabeth
Dakin, Paula
Maloney, Jennifer
Lu, Xin
Bauer, Deborah
Bansal, Ashish
Abdulai, Raolat
Robinson, Lacey
CHEST, 2024, 166 (04) : 4801A - 4805A
[10] In the Phase 3 Boreas Trial, Baseline Blood Eosinophils and Baseline Fractional Exhaled Nitric Oxide Levels Predict the Response to Dupilumab in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease and Type 2 Inflammation
Christenson, S.
Hanania, N. A.
Bhatt, S. P.
Bafadhel, M.
Rabe, K. F.
Vogelmeier, C. F.
Papi, A.
Singh, D.
Laws, E.
Nivens, M. C.
Bansal, A.
Lu, X.
Bauer, D.
Maloney, J.
Robinson, L. B.
Abdulai, R. M.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209

← 1 2 3 4 5 →